149 related articles for article (PubMed ID: 35315725)
21. Defining tropism and activity of natural and engineered extracellular vesicles.
Choi W; Park DJ; Eliceiri BP
Front Immunol; 2024; 15():1363185. PubMed ID: 38660297
[TBL] [Abstract][Full Text] [Related]
22. The Challenges and Possibilities of Extracellular Vesicles as Therapeutic Vehicles.
Melling GE; Carollo E; Conlon R; Simpson JC; Carter DRF
Eur J Pharm Biopharm; 2019 Nov; 144():50-56. PubMed ID: 31419585
[TBL] [Abstract][Full Text] [Related]
23. 3D cell culture stimulates the secretion of in vivo like extracellular vesicles.
Thippabhotla S; Zhong C; He M
Sci Rep; 2019 Sep; 9(1):13012. PubMed ID: 31506601
[TBL] [Abstract][Full Text] [Related]
24. Real-Time Luminescence Assay for Cytoplasmic Cargo Delivery of Extracellular Vesicles.
Somiya M; Kuroda S
Anal Chem; 2021 Apr; 93(13):5612-5620. PubMed ID: 33759512
[TBL] [Abstract][Full Text] [Related]
25. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer.
Godbole N; Quinn A; Carrion F; Pelosi E; Salomon C
Semin Cancer Biol; 2023 Nov; 96():64-81. PubMed ID: 37820858
[TBL] [Abstract][Full Text] [Related]
26. The CRISPR/Cas9 System Delivered by Extracellular Vesicles.
Zhu X; Gao M; Yang Y; Li W; Bao J; Li Y
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986843
[TBL] [Abstract][Full Text] [Related]
27. Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades").
Mangeot PE; Guiguettaz L; Sohier TJM; Ricci EP
J Vis Exp; 2021 Mar; (169):. PubMed ID: 33871447
[TBL] [Abstract][Full Text] [Related]
28. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
[TBL] [Abstract][Full Text] [Related]
29. Barriers to horizontal cell transformation by extracellular vesicles containing oncogenic H-ras.
Lee TH; Chennakrishnaiah S; Meehan B; Montermini L; Garnier D; D'Asti E; Hou W; Magnus N; Gayden T; Jabado N; Eppert K; Majewska L; Rak J
Oncotarget; 2016 Aug; 7(32):51991-52002. PubMed ID: 27437771
[TBL] [Abstract][Full Text] [Related]
30. CRISPR-Cas9-mediated pinpoint microbial genome editing aided by target-mismatched sgRNAs.
Lee HJ; Kim HJ; Lee SJ
Genome Res; 2020 May; 30(5):768-775. PubMed ID: 32327447
[TBL] [Abstract][Full Text] [Related]
31. Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy.
Chen R; Yuan W; Zheng Y; Zhu X; Jin B; Yang T; Yan Y; Xu W; Chen H; Gao J; Li G; Gokulnath P; Vulugundam G; Li J; Xiao J
J Nanobiotechnology; 2022 Jun; 20(1):304. PubMed ID: 35761332
[TBL] [Abstract][Full Text] [Related]
32. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
33. Gene Editing by Extracellular Vesicles.
Kostyushev D; Kostyusheva A; Brezgin S; Smirnov V; Volchkova E; Lukashev A; Chulanov V
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33028045
[TBL] [Abstract][Full Text] [Related]
34. The Roles of Extracellular Vesicles in Malignant Melanoma.
Cheng YC; Chang YA; Chen YJ; Sung HM; Bogeski I; Su HL; Hsu YL; Wang HD
Cells; 2021 Oct; 10(10):. PubMed ID: 34685720
[TBL] [Abstract][Full Text] [Related]
35. In Vivo therapeutic potential of mesenchymal stem cell-derived extracellular vesicles with optical imaging reporter in tumor mice model.
Kalimuthu S; Gangadaran P; Li XJ; Oh JM; Lee HW; Jeong SY; Lee SW; Lee J; Ahn BC
Sci Rep; 2016 Jul; 6():30418. PubMed ID: 27452924
[TBL] [Abstract][Full Text] [Related]
36. Extracellular vesicles from human liver stem cells inhibit renal cancer stem cell-derived tumor growth in vitro and in vivo.
Brossa A; Fonsato V; Grange C; Tritta S; Tapparo M; Calvetti R; Cedrino M; Fallo S; Gontero P; Camussi G; Bussolati B
Int J Cancer; 2020 Sep; 147(6):1694-1706. PubMed ID: 32064610
[TBL] [Abstract][Full Text] [Related]
37. Extracellular Vesicles Secreted by Atherogenic Macrophages Transfer MicroRNA to Inhibit Cell Migration.
Nguyen MA; Karunakaran D; Geoffrion M; Cheng HS; Tandoc K; Perisic Matic L; Hedin U; Maegdefessel L; Fish JE; Rayner KJ
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):49-63. PubMed ID: 28882869
[TBL] [Abstract][Full Text] [Related]
38. IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway.
Lombardo G; Gili M; Grange C; Cavallari C; Dentelli P; Togliatto G; Taverna D; Camussi G; Brizzi MF
Oncogene; 2018 Mar; 37(9):1175-1191. PubMed ID: 29238040
[TBL] [Abstract][Full Text] [Related]
39. Growth Media Conditions Influence the Secretion Route and Release Levels of Engineered Extracellular Vesicles.
Bost JP; Saher O; Hagey D; Mamand DR; Liang X; Zheng W; Corso G; Gustafsson O; Görgens A; Smith CE; Zain R; El Andaloussi S; Gupta D
Adv Healthc Mater; 2022 Mar; 11(5):e2101658. PubMed ID: 34773385
[TBL] [Abstract][Full Text] [Related]
40. Role of Extracellular Vesicle Surface Proteins in the Pharmacokinetics of Extracellular Vesicles.
Charoenviriyakul C; Takahashi Y; Morishita M; Nishikawa M; Takakura Y
Mol Pharm; 2018 Mar; 15(3):1073-1080. PubMed ID: 29382201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
